Baricitinib
CAS 1187594-09-7 8 FDA-DMF suppliersSmall Molecule
Overview
Baricitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis. It is also under investigation for other autoimmune and inflammatory conditions.
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Baricitinib expires 30 Nov 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
RheumatologyImmunologyDermatology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.